Skip to main content
GoodMoatv1.3
Sign in
PFE logo

PFE

CompareEarnings: May 31, 2026

Pfizer Inc

Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).

Did you know?

Free cash flow has been growing at -2.5% annually.

Current Price

$26.67

-0.49%

GoodMoat Value

$17.95

32.7% overvalued
Profile
Valuation (TTM)
Market Cap$151.64B
P/E19.52
EV$203.41B
P/B1.75
Shares Out5.69B
P/Sales2.42
Revenue$62.58B
EV/EBITDA14.39

Pfizer Inc (PFE) Company Profile

GoodMoat Analysis

Based on data as of March 26, 2026

Pfizer is a pharmaceutical giant with a strong brand and patent-protected moat, but it faces significant post-pandemic revenue declines and patent expirations. A value investor might be interested in its high dividend yield and low P/E, but must weigh these against weak growth and high red flags.

Read full analysis
Pfizer Inc. is one of the world's largest pharmaceutical companies. Its business model involves discovering, developing, manufacturing, and marketing prescription medicines and vaccines. Its primary customers are wholesalers, pharmacies, hospitals, and government health programs. The company's moat, as per the framework, is primarily built on **Regulatory Barriers** and **Brand & Culture**. It holds exclusive patents on blockbuster drugs like Paxlovid and Comirnaty (the COVID-19 vaccine), granting it temporary monopolies. Its global brand recognition and deep R&D capabilities are significant advantages. However, applying the Moat Identification criteria yields a likely low score; beyond patents and brand, evidence for durable advantages like high switching costs or proprietary data is less clear, especially as key patents expire. The data shows major risks aligning with Section 5 Red Flags. There is **High Customer Concentration** risk through government vaccine contracts, **Growth Deceleration** with revenue growth at -1.2% YoY, and potential **Competitive Erosion** as patents for major drugs will expire in the coming years, opening the door to generic competition. The GoodMoat Target price of $17.95, significantly below the current price, signals a cautionary view on valuation. A value investor might see a favourable P/E of 19.96 and a high dividend yield of 6.30%, but must carefully consider if these compensate for the challenging growth trajectory and the multiple red flags present.

PFE Company Information

At Pfizer Oncology, we are at the forefront of a new era in cancer care.

Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics.

We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer.

Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.

Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.

Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp. , a subsidiary of Merck & Co. , Inc.

, Rahway, NJ, USA (known as MSD outside of the United States and Canada).

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYSE

Country

New York, USA

PFE Key Officers

Key officers data coming soon

PFE Company Profile

Pfizer Inc (PFE) is a Healthcare company in the Drug Manufacturers - General industry. It trades on NYSE. The company is based in New York, USA.

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).

Market cap is $151.64B. There are 5685.7M shares outstanding. Dividend yield is 6.44%.

See the full Pfizer Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if PFE is a good investment.